Also trades as: 4502.T (JPX) · $vol 168M · TAK (NYSE) · $vol 60M

$41.15

-0.07 (-0.17%)

After Hours: $40.11 (-1.04, -2.52%)

Weekly Expected Move ±8.1%

$35 $38 $41 $45 $48

OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Buy · Power 74 · $63.3B mcap · 1.58B float · 0.0006% daily turnover · Short 80% of daily vol

Credit Risk of going bust: lower than 78% of companies Debt: 32.5% of company value Bonds: none of note held by US funds details ▾

If the stock fell to about $0.99 (down 98%), Takeda Pharmaceutical Company Limited would be worth roughly what it owes.
Total debt $31.37B against a stock market value of $65.02B.
Distance to default 9.16 (Merton model): prices to 2026-10-23, balance sheet 2026-06-30, debt counted $17.34B (short-term plus half of long-term), stock volatility 21.6%; Altman Z'' 1.53. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Overview Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest

Income Trends

Revenue

$4.58T +7.5% ▲

5Y CAGR: +6.8%

Gross Profit

$3.00T +6.0% ▲

5Y CAGR: +6.4%

Operating Income

$342.6B +60.0% ▲

5Y CAGR: +27.8%

Net Income

$107.9B -25.1% ▼

5Y CAGR: +19.5%

EPS (Diluted)

$67.23 -26.3% ▼

5Y CAGR: +18.9%

EBITDA

$1.07T +19.3% ▲

5Y CAGR: +9.8%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2020	FY2021	FY2022	FY2023	FY2024
Revenue	$3.20T	$3.57T	$4.03T	$4.26T	$4.58T
YoY Growth	-2.8%	+11.6%	+12.8%	+5.9%	+7.5%
Cost of Revenue	$994.3B	$1.11T	$1.24T	$1.43T	$1.58T
Gross Profit	$2.20T	$2.46T	$2.78T	$2.83T	$3.00T
Gross Margin	68.9%	69.0%	69.1%	66.4%	65.5%
R&D Expenses	$455.8B	$526.1B	$633.3B	$729.9B	$730.2B
SG&A Expenses	$875.7B	$886.4B	$997.3B	$1.05T	$1.10T
Operating Expenses	$1.69T	$2.00T	$2.29T	$2.62T	$2.66T
Operating Income	$509.3B	$460.8B	$490.5B	$214.1B	$342.6B
Operating Margin	15.9%	12.9%	12.2%	5.0%	7.5%
Interest Expense	$248.6B	$166.6B	$169.7B	$119.5B	$137.3B
Income Before Tax	$366.2B	$302.6B	$375.1B	$52.8B	$175.1B
Tax Expense	-$9.9B	$72.4B	$58.1B	-$91.4B	$66.9B
Net Income	$376.0B	$230.1B	$317.0B	$144.1B	$107.9B
Net Margin	11.8%	6.4%	7.9%	3.4%	2.4%
EPS (Diluted)	$238.96	$145.87	$201.94	$91.16	$67.23
EBITDA	$1.06T	$1.01T	$1.16T	$900.3B	$1.07T
Shares Outstanding	1.57B	1.58B	1.57B	1.58B	1.61B

Line Item	FY2024 Q2	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1
Revenue	$1.18T	$1.14T	$1.05T	$1.11T	$1.11T	$1.19T	$1.10T	$1.22T
Cost of Revenue	$394.3B	$416.9B	$382.1B	$384.7B	$380.1B	$543.5B	$564.1B	$406.7B
Gross Profit	$781.7B	$727.2B	$671.3B	$722.0B	$732.7B	$649.2B	$537.4B	$813.2B
Gross Margin	66.5%	63.6%	63.7%	65.2%	65.8%	54.4%	48.8%	66.7%
R&D Expenses	$175.6B	$170.2B	$216.0B	$143.9B	$161.5B	$175.4B	$196.5B	$167.4B
SG&A Expenses	$268.3B	$270.6B	$295.9B	$255.9B	$253.6B	$283.0B	$293.8B	$286.5B
Operating Expenses	$597.5B	$660.3B	$746.3B	$537.4B	$663.7B	$458.4B	$490.4B	$611.8B
Operating Income	$184.2B	$66.9B	-$74.9B	$184.6B	$69.0B	$190.8B	$47.0B	$201.4B
Operating Margin	15.7%	5.9%	-7.1%	16.7%	6.2%	16.0%	4.3%	16.5%
Interest Expense	$68.5B	$31.6B	$22.4B	$107.2B	$83.1B	$123.7B	$43.9B	$63.8B
Income Before Tax	$119.4B	$26.4B	-$107.3B	$150.6B	$28.2B	$134.0B	-$52.8B	$162.7B
Tax Expense	$27.3B	$2.6B	-$4.2B	$26.4B	$39.9B	$30.2B	-$28.4B	$49.5B
Net Income	$92.0B	$23.8B	-$103.2B	$124.2B	-$11.8B	$103.7B	-$24.5B	$113.2B
Net Margin	7.8%	2.1%	-9.8%	11.2%	-1.1%	8.7%	-2.2%	9.3%
EPS (Diluted)	$57.17	$14.78	$-65.25	$78.23	$-7.48	$64.73	$-15.66	$70.54
EBITDA	$380.3B	$245.0B	$73.3B	$439.4B	$316.5B	$448.5B	$211.9B	$337.5B
Shares Outstanding	1.61B	1.61B	1.58B	1.59B	1.58B	1.60B	1.56B	1.60B

TKPHF OTC

Income Trends

Profit Margins

Year-over-Year Growth

Sign in to InsiderStreet